Latest Research And Development News

AFT Pharmaceuticals reports a robust 33% revenue increase in the first half of FY26, driven by strong ANZ market performance and expanding international presence. The company advances its R&D pipeline and targets NZ$300 million revenue for FY27 amid strategic global expansion.

AFT Pharmaceuticals delivered a robust first half for FY26, posting 33% revenue growth and a return to profitability, driven by strong Australian sales and recovery in Asia and international markets. The company is advancing its global footprint and R&D pipeline, positioning for sustained growth.

AFT Pharmaceuticals has reported a robust first half of FY26, posting a 33% revenue increase to a record $114.9 million and returning to profitability amid strong growth in Australia and international markets. The company’s advancing R&D pipeline and strategic licensing deals position it well for ambitious FY27 targets.

Nufarm Limited posted a $165.3 million statutory loss for FY25, driven by significant restructuring charges and omega-3 price declines, while announcing a CEO transition effective January 2026.

Clover Corporation Limited reported a standout FY25 with robust revenue growth and a sharp rise in profitability, underpinned by strategic market expansion and product innovation. The company’s strengthened balance sheet and optimistic FY26 outlook signal continued momentum.

TechnologyOne has reported a robust FY25 with profit before tax up 19% and ARR reaching $554.6 million, propelled by its SaaS+ platform and UK market expansion. The company sets an ambitious $1 billion ARR target by FY30, underpinned by strong R&D investment and AI integration.

TechnologyOne has delivered a standout FY25 performance, beating profit guidance and accelerating its ARR growth well ahead of schedule, powered by its innovative SaaS+ model and strong UK market traction.

Critical Resources Limited has secured a 12-month exclusive option to evaluate advanced solid-state lithium-ion battery technology from the South Dakota School of Mines & Technology, aiming to enhance battery safety, performance, and commercial potential.

Catapult Sports Ltd has reported a robust first half of FY26, with a 19% increase in Annualized Contract Value and a 50% jump in operating profit, driven by strategic acquisitions and strong SaaS growth.

Aurora Labs has entered a strategic MOU with Ares Armaments to co-develop advanced metal components for defence, aiming to revolutionise small-arms manufacturing with additive technology.

Algorae Pharmaceuticals has announced a non-renounceable Loyalty Options Offer to eligible shareholders, aiming to raise up to $337,678 before costs, with potential additional capital of $4.7 million if all options are exercised. The capital raise supports the company’s pharmaceutical and AI research and development ambitions.

Genetic Signatures Limited unveiled a year of strategic transformation and robust financial growth at its 2025 AGM, highlighting leadership renewal and a sharpened commercial focus. The company’s FY25 revenue jumped 66%, driven by strong product demand and expanded market presence.